NL-OMON24282已完成不适用
Vroege voorspelling adalimumab spiegels met InsightRx
Máxima Medisch Centrum0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •All adult patients over 18 years of age with new adalimumab prescriptions at initial dosing interval of 14 days for rheumatic diseases (RA,PsA,SpA) or inflammatory bowel disease (UC, Crohn’s disease) will be eligible to participate in our study.
排除标准
- •Pregnancy • Previous adalimumab use • Allergy for adalimumab or excipients (Humira) • Patients unable or unwilling to consent to participation to this trial
研究者
相似试验
已完成
不适用
Early prediction of adalimumab levels with InsightRxPsoriatic ArthritisInflammatory Bowel Diseases (M.Crohn and Ulcerative Colitis) and Rheumatic diseases (Rheumatoid ArthritisSpondyloarthropathy)1001796910023213NL-OMON49110Maxima Medisch Centrum40
已完成
2 期
Evaluating the effects of Adalimumab in patients with acute respiratory distress syndrome caused by COVID-19IRCT20151227025726N23Shahid Beheshti University of Medical Sciences60
已完成
2 期
Adalimumab effectiveness in COVID-19COVID-19.C0VID-19U07.1IRCT20150303021315N22Tehran University of Medical Sciences40
招募中
不适用
FKB327 Registry Studylcerative Colitis, Crohn's Disease, Psoriatic ArthritisUlcerative Colitis, Crohn's Disease, Psoriatic ArthritisD003093, D003424, D015535JPRN-jRCT1031210582ozawa Kazutaka300
进行中（未招募）
不适用
Evaluation of the efficacy and safety of adalimumab (Humira) s.c. injections eow. in patients with adhesive capsulitis (frozen shoulder). - The TEST TrialEUCTR2006-005426-23-DKPierre Schydlowsky